Literature DB >> 5336955

Infectious mononucleosis.

J Joncas.   

Abstract

A short review of past and recent works pertinent to the etiology and pathogenesis of infectious mononucleosis is presented. Epidemiological studies have led to the elaboration of hypotheses concerning the etiology, the length of the incubation period and the mode of transmission of the disease. An unusual type of infectious mononucleosis of rickettsial origin has been reported by Japanese workers. Studies of accidental and experimental transmission suggest that more than one agent may give rise to the same disease. Isolation attempts in tissue cultures have been unrewarding except for the uncovering of possible agents by interference and immunofluorescence.The atypical lymphocyte is the site of increased RNA and DNA synthesis. It does not seem to be involved in antibody synthesis. The heterophile agglutinins and other mononucleosis-associated antibodies apparently account for only part of the excess 19S antibody material found in mononucleosis sera. The origin and function of these antibodies and of the atypical lymphocyte are the subject of speculation.The final elucidation of the pathogenesis of the disease and the confirmation of the reviewed hypotheses are all dependent on the eventual discovery of the elusive etiological agent(s) of infectious mononucleosis.

Mesh:

Year:  1967        PMID: 5336955      PMCID: PMC1922851     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  44 in total

1.  STUDIES ON HUMAN LEUKEMIA. II. STRUCTURE AND QUANTITATION OF MYXOVIRUS-LIKE PARTICLES ASSOCIATED WITH HUMAN LEUKEMIA.

Authors:  K O SMITH; M BENYESH-MELNICK; D J FERNBACH
Journal:  J Natl Cancer Inst       Date:  1964-09       Impact factor: 13.506

2.  THE "INFECTIOUS MONONUCLEOSIS CELL". A CYTOCHEMICAL STUDY.

Authors:  P GALBRAITH; W J MITUS; M GOLLERKERI; W DAMESHEK
Journal:  Blood       Date:  1963-11       Impact factor: 22.113

3.  REACTIONS OF HUMAN SERA WITH MAMMALIAN CELL CULTURES.

Authors:  K KANO; F MILGROM; A L BARRON; E WITEBSKY
Journal:  J Immunol       Date:  1965-03       Impact factor: 5.422

4.  Serum enzymes in disease. IX. Analysis of factors responsible for elevated values in infectious mononucleosis.

Authors:  D GELB; M WEST; H J ZIMMERMAN
Journal:  Am J Med       Date:  1962-08       Impact factor: 4.965

5.  The nature of the Newcastle agglutinin in infectious mononucleosis and infective hepatitis.

Authors:  R H SWAIN
Journal:  J Pathol Bacteriol       Date:  1959-07

6.  [Relationships of infectious mononucleosis and rickettsial diseases].

Authors:  P GIROUD; M CAPPONI; N DUMAS
Journal:  Nouv Rev Fr Hematol       Date:  1961 Mar-Apr

7.  [The platelets in infectious mononucleosis].

Authors:  B MAUPIN; R MONTEIL
Journal:  Nouv Rev Fr Hematol       Date:  1961 Mar-Apr

8.  Studies on infectious mononucleosis: I. Cytopathic agents and immunofluorescence studies.

Authors:  J Joncas; A Chagnon; V Pavilanis
Journal:  Can Med Assoc J       Date:  1966-05-07       Impact factor: 8.262

9.  The mitotic activity of circulating atypical mononuclear cells in infectious mononucleosis.

Authors:  R L Carter
Journal:  Blood       Date:  1965-11       Impact factor: 22.113

10.  Postperfusion syndrome. Report of four cases and review of the literature.

Authors:  T A Riemenschneider; A J Moss
Journal:  J Pediatr       Date:  1966-10       Impact factor: 4.406

View more
  3 in total

1.  Serological response of the EBV antibodies in pediatric cases of infectious mononucleosis and in their contacts.

Authors:  J Joncas; C Mitnyan
Journal:  Can Med Assoc J       Date:  1970-06-06       Impact factor: 8.262

2.  Studies on infectious mononucleosis. 3. Clinical data, serologic and epidemiologic findings.

Authors:  J Joncas; J P Chiasson; J Turcotte; P Quennec
Journal:  Can Med Assoc J       Date:  1968-05-04       Impact factor: 8.262

Review 3.  Infectious mononucleosis: current status of candidate virus.

Authors:  J H Joncas
Journal:  Can Med Assoc J       Date:  1969-07-12       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.